Open Payments

Univ Of Missouri Health Care

Type
Teaching hospital
Where
COLUMBIA, MO
Medicare CCN
260141
Received
$10,005,286 in 646 records, 2022 ($6,448,646 general, $3,556,640 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2022General payment226$6,448,646
2022Research payment420$3,556,640

By company

CompanyRecordsAmountYears
Advanced Accelerator Applications46$5,132,8012022
ModernaTX, Inc.60$1,177,3532022
LANTHEUS MEDICAL IMAGING, INC.3$482,9452022
JAZZ PHARMACEUTICALS INC.1$349,3032022
Cognoa, Inc.2$250,0002022
Arthrex, Inc.12$169,6092022
Siemens Medical Solutions USA, Inc.13$161,3002022
Medtronic, Inc.30$144,1582022
Olympus Corporation of the Americas2$144,0682022
ROCHE MOLECULAR SYSTEMS, INC.8$142,3412022
VERTEX PHARMACEUTICALS INCORPORATED2$137,3002022
Otsuka Pharmaceutical Development & Commercialization, Inc.2$111,4052022
Novartis Pharmaceuticals Corporation2$95,3242022
LivaNova USA, Inc.21$90,4552022
Boehringer Ingelheim Pharmaceuticals, Inc.3$89,2922022
Baxter Healthcare6$76,1432022
Regeneron Pharmaceuticals, Inc.24$74,7922022
Ortho-Clinical Diagnostics, Inc.9$71,3192022
Synthes GmbH4$71,0002022
BioMarin Pharmaceutical Inc.17$64,9102022
Alexion Pharmaceuticals, Inc.4$59,2932022
AstraZeneca Pharmaceuticals LP4$51,5072022
Veryan Medical Incorporated4$49,7262022
GENZYME CORPORATION12$43,3002022
Merck Sharp & Dohme LLC13$40,9002022
Bioventus LLC1$40,1112022
ABBVIE INC.7$38,9882022
Medical Device Business Services, Inc.21$38,9082022
Stryker Corporation20$36,1452022
BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.18$35,3232022
UROGEN PHARMA, INC.13$34,7222022
Ethicon Endo-Surgery Inc.9$33,3162022
AKEBIA THERAPEUTICS INC2$32,2002022
Merz Pharmaceuticals, LLC7$29,9802022
CSL Behring38$28,1922022
Takeda Pharmaceuticals U.S.A., Inc.8$25,3402022
Ipsen Pharma SAS10$23,0452022
UCB SA2$21,9502022
Tandem Diabetes Care, Inc.28$20,5002022
Innovation Technologies Inc9$19,6672022
EMD Serono, Inc.7$19,5392022
Alcon Vision LLC1$18,0002022
Optinose US, Inc.6$16,8382022
Olympus America Inc.1$16,7752022
Linde Gas & Equipment Inc.33$15,5892022
W. L. Gore & Associates, Inc.1$15,0002022
Grifols Therapeutics LLC5$14,8282022
SANOFI US SERVICES INC.2$12,7012022
ALK-Abello, Inc3$11,9902022
Becton, Dickinson and Company6$11,3752022

By nature of payment

NatureRecordsAmount
Compensation for services other than consulting, including serving as faculty or as a speaker at a v100$5,792,747
Research payment420$3,556,640
Grant16$273,398
Consulting Fee13$204,639
Space rental or facility fees (teaching hospital only)78$68,349
Education2$55,000
Debt forgiveness5$22,653
Royalty or License2$20,365
Long term medical supply or device loan4$9,050
Charitable Contribution6$2,441

Records

DateCompanyAmountNatureFormProductStudyYear
2022-12-31Merck Sharp & Dohme LLC$12,681Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand2022
2022-12-31Merck Sharp & Dohme LLC$7,283Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiot2022
2022-12-31AstraZeneca Pharmaceuticals LP$6,217Research paymentIn-kind items and servicesTEZSPIRE Biological, RespiratoryA Multicenter Randomized Double Blind Parallel Group Placebo Controlled Phase 3 Efficacy and Safety Study of Tezepelumab2022
2022-12-31Merck Sharp & Dohme LLC$5,202Research paymentIn-kind items and servicesVERQUVO Drug, CARDIOVASCULARA Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulato2022
2022-12-31Stryker Corporation$4,506Debt forgivenessCash or cash equivalent2022
2022-12-31Merck Sharp & Dohme LLC$4,125Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand2022
2022-12-31Merck Sharp & Dohme LLC$3,852Research paymentIn-kind items and servicesLENVIMA Drug, ONCOLOGYA Phase 3, randomized, double-blind trial of pembrolizumab MK-3475 with or without lenvatinib E7080,MK-7902 in participa2022
2022-12-31ABBVIE INC.$2,065Research paymentIn-kind items and servicesBOTOX Biological, FACIAL AESTHETICSStudy of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor2022
2022-12-31Merck Sharp & Dohme LLC$1,459Research paymentIn-kind items and servicesLENVIMA Drug, ONCOLOGYA Phase 3, randomized, double-blind trial of pembrolizumab MK-3475 with or without lenvatinib E7080,MK-7902 in participa2022
2022-12-31Merck Sharp & Dohme LLC$989Research paymentIn-kind items and servicesVERQUVO Drug, CARDIOVASCULARA Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulato2022
2022-12-31Stryker Corporation$888Debt forgivenessCash or cash equivalent2022
2022-12-31AstraZeneca UK Limited$684Research paymentIn-kind items and servicesA Phase 2/3 Randomized, Double-blind, Palivizumab-controlled Study to Evaluate the Safety of MEDI8897, a Monoclonal Anti2022
2022-12-31UROGEN PHARMA, INC.$392Research paymentIn-kind items and servicesUROGEN PHARMA BL0112022
2022-12-31Merck Sharp & Dohme LLC$136Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand2022
2022-12-31Merck Sharp & Dohme LLC$23Research paymentIn-kind items and servicesBRIDION Drug, NEUROSCIENCEA Phase 4 Randomized, Active-Comparator Controlled Clinical Trial to Study the Safety of Sugammadex MK-8616 for the Reve2022
2022-12-31Merck Sharp & Dohme LLC$23Research paymentIn-kind items and servicesBRIDION Drug, NEUROSCIENCEA Phase 4 Randomized, Active-Comparator Controlled Clinical Trial to Study the Safety of Sugammadex MK-8616 for the Reve2022
2022-12-31AstraZeneca UK Limited$4Research paymentIn-kind items and servicesA Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclon2022
2022-12-28Regeneron Pharmaceuticals, Inc.$1,310Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYREGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID)2022
2022-12-23ModernaTX, Inc.$11,558Research paymentCash or cash equivalentModerna Covid-19 Vaccine Biological, Infections and Infectious DiseasesA Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled2022
2022-12-23ViiV Healthcare Company$4,528Research paymentCash or cash equivalentA PHASE 4, RANDOMIZED, OPEN-LABEL, TWO-ARM STUDY EVALUATING IMPLEMENTA2022
2022-12-22UROGEN PHARMA, INC.$14,813Research paymentCash or cash equivalentBL0112022
2022-12-22Linde Gas & Equipment Inc.$330Space rental or facility fees (teaching hospital only)In-kind items and servicesREQNOXBOX-I Device, Respiratory2022
2022-12-21ModernaTX, Inc.$5,022Research paymentCash or cash equivalentModerna Covid-19 Vaccine Biological, Infections and Infectious DiseasesA Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled2022
2022-12-21ROCHE MOLECULAR SYSTEMS, INC.$5,000Consulting FeeCash or cash equivalent Device2022
2022-12-21BioMarin Pharmaceutical Inc.$98Research paymentCash or cash equivalentAn Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia2022
2022-12-19Advanced Accelerator Applications$348,331Compensation for services other than consulting, including serving as faculty or as a speaker at a v (6 payments)Cash or cash equivalentLUTATHERA Drug, Oncology2022
2022-12-19Advanced Accelerator Applications$266,547Compensation for services other than consulting, including serving as faculty or as a speaker at a v (6 payments)Cash or cash equivalentLUTATHERA Drug, Oncology2022
2022-12-19Advanced Accelerator Applications$245,836Compensation for services other than consulting, including serving as faculty or as a speaker at a v (4 payments)Cash or cash equivalentLUTATHERA Drug, Oncology2022
2022-12-19Advanced Accelerator Applications$235,237Compensation for services other than consulting, including serving as faculty or as a speaker at a v (5 payments)Cash or cash equivalentLUTATHERA Drug, Oncology2022
2022-12-19Advanced Accelerator Applications$158,246Compensation for services other than consulting, including serving as faculty or as a speaker at a v (4 payments)Cash or cash equivalentLUTATHERA Drug, Oncology2022
2022-12-16Baxter Healthcare$4,400Space rental or facility fees (teaching hospital only)Cash or cash equivalentRenal - HD Device, Renal2022
2022-12-16Baxter Healthcare$4,400Space rental or facility fees (teaching hospital only)Cash or cash equivalentRenal - HD Device, Renal2022
2022-12-16Innovation Technologies Inc$1,160Research paymentCash or cash equivalentIRRISEPT Device, JET LAVAGE DEVICE WITH CHGPROSPECTIVE RANDOMIZED CONTROL TRIAL COMPARING TEMPORARY EXTERNAL FIXATOR TO ANTIBIOTIC-COATED IM NAIL FOR OPEN TIBIA FR2022
2022-12-16CSL Behring$684Research paymentCash or cash equivalentA Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a2022
2022-12-16ModernaTX, Inc.$619Research paymentCash or cash equivalentModerna Covid-19 Vaccine Biological, Infections and Infectious DiseasesA Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled2022
2022-12-16PFIZER INC.$416Research paymentCash or cash equivalent2022
2022-12-15Arthrex, Inc.$4,863Research paymentCash or cash equivalentDISTAL EXTREMITIES INSTRUMENTS TRAUMA KNEE TRAUMA Device, DISTAL EXTREMITIES - INSTRUMENTS - TRAUMA - KNEE TRAUMABiomechanical Comparison of Nitinol Compression Staples Versus Fully Threaded Lag Screws for Talonav2022
2022-12-15Medtronic, Inc.$3,995Research paymentCash or cash equivalentMICRA Device, PacemakersPSR-CVG2022
2022-12-15Medtronic, Inc.$1,089Research paymentCash or cash equivalentMICRA Device, PacemakersPSR-CVG2022
2022-12-15Linde Gas & Equipment Inc.$330Space rental or facility fees (teaching hospital only)In-kind items and servicesREQNOXBOX-I Device, Respiratory2022
2022-12-15Medtronic, Inc.$68Research paymentCash or cash equivalentMICRA Device, PacemakersPSR-CVG2022
2022-12-15Medtronic, Inc.$68Research paymentCash or cash equivalentMICRA Device, PacemakersPSR-CVG2022
2022-12-14LivaNova USA, Inc.$301Research paymentCash or cash equivalentVNS Therapy Symmetry Model 8103 Generator Device, Cardiology/Vascular DiseasesA Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Thera2022
2022-12-13Linde Gas & Equipment Inc.$330Space rental or facility fees (teaching hospital only)In-kind items and servicesREQNOXBOX-I Device, Respiratory2022
2022-12-12Advanced Accelerator Applications$58,066Compensation for services other than consulting, including serving as faculty or as a speaker at a v (5 payments)Cash or cash equivalentLUTATHERA Drug, Oncology2022
2022-12-12Advanced Accelerator Applications$3,969Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentLUTATHERA Drug, Oncology2022
2022-12-10Linde Gas & Equipment Inc.$330Space rental or facility fees (teaching hospital only)In-kind items and servicesREQNOXBOX-I Device, Respiratory2022
2022-12-09ModernaTX, Inc.$14,970Research paymentCash or cash equivalentModerna Covid-19 Vaccine Biological, Infections and Infectious DiseasesA Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled2022
2022-12-09ModernaTX, Inc.$1,740Research paymentCash or cash equivalentModerna Covid-19 Vaccine Biological, Infections and Infectious DiseasesA Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled2022
2022-12-08EMD Serono, Inc.$839Research paymentCash or cash equivalentA Randomized, Double-Blind Placebo-Controlled, Phase 3 Study of Debio 1143 in Combination With Platinum-Based Chemothera2022
2022-12-07Ortho-Clinical Diagnostics, Inc.$10,419Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentVITROS XT 3400 Chemistry System Device, DIAGNOSTICS2022
2022-12-07Ortho-Clinical Diagnostics, Inc.$9,190Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentVITROS XT 3400 Chemistry System Device, DIAGNOSTICS2022
2022-12-07Ortho-Clinical Diagnostics, Inc.$2,760Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentVITROS 3600 Immunodiagnostic System Device, DIAGNOSTICS2022
2022-12-07ModernaTX, Inc.$2,377Research paymentCash or cash equivalentModerna Covid-19 Vaccine Biological, Infections and Infectious DiseasesA Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled2022
2022-12-06Becton, Dickinson and Company$4,734Research paymentIn-kind items and servicesISS 718560572022
2022-12-05AXOGEN$10,360Research paymentCash or cash equivalentAVANCE NERVE GRAFTRegistry of Avance Nerve Graft's Utilization and Recovery Outcomes Post Peripheral Nerve Reconstruction (RANGER)2022
2022-12-05GENZYME CORPORATION$5,250Research paymentCash or cash equivalentFabry LSD Data Registry2022
2022-12-05GENZYME CORPORATION$925Research paymentCash or cash equivalentPompe LSD Data Registry2022
2022-12-05GENZYME CORPORATION$50Research paymentCash or cash equivalentGaucher LSD Data Registry2022
2022-12-01LivaNova USA, Inc.$1,932Research paymentCash or cash equivalentVNS Therapy Symmetry Model 8103 Generator Device, Cardiology/Vascular DiseasesA Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Thera2022
2022-12-01ModernaTX, Inc.$1,786Research paymentCash or cash equivalentModerna Covid-19 Vaccine Biological, Infections and Infectious DiseasesA Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled2022
2022-12-01Regeneron Pharmaceuticals, Inc.$1,108Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)2022
2022-12-01Regeneron Pharmaceuticals, Inc.$988Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)2022
2022-12-01Regeneron Pharmaceuticals, Inc.$672Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)2022
2022-12-01Regeneron Pharmaceuticals, Inc.$642Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)2022
2022-11-30Tandem Diabetes Care, Inc.$1,100Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt:slim X2 Insulin Pump with Control-IQ Device, Endocrinology2022
2022-11-30Linde Gas & Equipment Inc.$330Space rental or facility fees (teaching hospital only)In-kind items and servicesREQNOXBOX-I Device, Respiratory2022
2022-11-29Takeda Pharmaceuticals U.S.A., Inc.$530Research paymentCash or cash equivalentNATPARA (PARATHYROID HORMONE) Drug, INTERNAL MEDICINEPARADIGHM A NATURAL HISTORY REGISTRY FOR PATIENTS WITH CHRONIC HYPOPARATHYROIDISM2022
2022-11-28Novo Nordisk AS$700Research paymentCash or cash equivalentOzempic Drug, DiabetesNN9535-44162022
2022-11-25ModernaTX, Inc.$9,463Research paymentCash or cash equivalentModerna Covid-19 Vaccine Biological, Infections and Infectious DiseasesA Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled2022
2022-11-25Medical Device Business Services, Inc.$1,047Research paymentCash or cash equivalentDePuy Synthes Lower Extremity Shaft Nail Registry (RFN-Advanced Retrograde Femoral Nailing System/ TN-Advanced Tibial Na2022
2022-11-25Medical Device Business Services, Inc.$1,047Research paymentCash or cash equivalentDePuy Synthes Lower Extremity Shaft Nail Registry (RFN-Advanced Retrograde Femoral Nailing System/ TN-Advanced Tibial Na2022
2022-11-24BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.$7,000Research paymentCash or cash equivalentNURTEC ODT Drug, PRIMARY CAREA Phase 2/3 Double-Blind Randomized Placebo-Controlled Safety and Efficacy Trial of BHV-3000 (rimegepant) Orally Disinte2022
2022-11-24BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.$1,878Research paymentCash or cash equivalentNURTEC ODT Drug, PRIMARY CAREA Phase 2/3 Double-Blind Randomized Placebo-Controlled Safety and Efficacy Trial of BHV-3000 (rimegepant) Orally Disinte2022
2022-11-24BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.$1,878Research paymentCash or cash equivalentNURTEC ODT Drug, PRIMARY CAREA Phase 2/3 Double-Blind Randomized Placebo-Controlled Safety and Efficacy Trial of BHV-3000 (rimegepant) Orally Disinte2022
2022-11-24BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.$1,878Research paymentCash or cash equivalentNURTEC ODT Drug, PRIMARY CAREA Phase 2/3 Double-Blind Randomized Placebo-Controlled Safety and Efficacy Trial of BHV-3000 (rimegepant) Orally Disinte2022
2022-11-24BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.$1,878Research paymentCash or cash equivalentNURTEC ODT Drug, PRIMARY CAREA Phase 2/3 Double-Blind Randomized Placebo-Controlled Safety and Efficacy Trial of BHV-3000 (rimegepant) Orally Disinte2022
2022-11-24BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.$1,878Research paymentCash or cash equivalentNURTEC ODT Drug, PRIMARY CAREA Phase 2/3 Double-Blind Randomized Placebo-Controlled Safety and Efficacy Trial of BHV-3000 (rimegepant) Orally Disinte2022
2022-11-24BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.$1,637Research paymentCash or cash equivalentNURTEC ODT Drug, PRIMARY CAREA Phase 2/3 Double-Blind Randomized Placebo-Controlled Safety and Efficacy Trial of BHV-3000 (rimegepant) Orally Disinte2022
2022-11-24BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.$1,500Research paymentCash or cash equivalentNURTEC ODT Drug, PRIMARY CAREA Phase 2/3 Double-Blind Randomized Placebo-Controlled Safety and Efficacy Trial of BHV-3000 (rimegepant) Orally Disinte2022
2022-11-23ModernaTX, Inc.$24,929Research paymentCash or cash equivalentA Study to Evaluate the Safety and Immunogenicity of the mRNA-1273.214 COVID-19 Vaccine in Healthy Children Between 6 Mo2022
2022-11-23EMD Serono, Inc.$12,206Research paymentCash or cash equivalentA Randomized, Double-Blind Placebo-Controlled, Phase 3 Study of Debio 1143 in Combination With Platinum-Based Chemothera2022
2022-11-23ModernaTX, Inc.$5,000Research paymentCash or cash equivalentModerna Covid-19 Vaccine Biological, Infections and Infectious DiseasesA Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled2022
2022-11-23ModernaTX, Inc.$3,930Research paymentCash or cash equivalentModerna Covid-19 Vaccine Biological, Infections and Infectious DiseasesA Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled2022
2022-11-23Stryker Corporation$3,480Research paymentCash or cash equivalentTRITANIUM Device, HIPSTRIATHLON TRITANIUM CONE AUGMENTS OUTCOMES STUDY2022
2022-11-23ModernaTX, Inc.$3,144Research paymentCash or cash equivalentModerna Covid-19 Vaccine Biological, Infections and Infectious DiseasesA Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled2022
2022-11-23ModernaTX, Inc.$3,144Research paymentCash or cash equivalentModerna Covid-19 Vaccine Biological, Infections and Infectious DiseasesA Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled2022
2022-11-23EMD Serono, Inc.$1,838Research paymentCash or cash equivalentA Randomized, Double-Blind Placebo-Controlled, Phase 3 Study of Debio 1143 in Combination With Platinum-Based Chemothera2022
2022-11-23ModernaTX, Inc.$327Research paymentCash or cash equivalentModerna Covid-19 Vaccine Biological, Infections and Infectious DiseasesA Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled2022
2022-11-23UROGEN PHARMA, INC.$76Research paymentIn-kind items and servicesUROGEN PHARMA BL0112022
2022-11-23UROGEN PHARMA, INC.$71Research paymentIn-kind items and servicesUROGEN PHARMA BL0112022
2022-11-23ModernaTX, Inc.$52Research paymentCash or cash equivalentModerna Covid-19 Vaccine Biological, Infections and Infectious DiseasesA Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled2022
2022-11-23ModernaTX, Inc.$19Research paymentCash or cash equivalentModerna Covid-19 Vaccine Biological, Infections and Infectious DiseasesA Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled2022
2022-11-22LivaNova USA, Inc.$3,419Research paymentCash or cash equivalentVNS Therapy Symmetry Model 8103 Generator Device, Cardiology/Vascular DiseasesA Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Thera2022
2022-11-22BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.$1,741Research paymentCash or cash equivalentNURTEC ODT Drug, PRIMARY CAREA Phase 2/3 Double-Blind Randomized Placebo-Controlled Safety and Efficacy Trial of BHV-3000 (rimegepant) Orally Disinte2022
2022-11-22Innovation Technologies Inc$1,160Research paymentCash or cash equivalentIRRISEPT Device, JET LAVAGE DEVICE WITH CHGPROSPECTIVE RANDOMIZED CONTROL TRIAL COMPARING TEMPORARY EXTERNAL FIXATOR TO ANTIBIOTIC-COATED IM NAIL FOR OPEN TIBIA FR2022
2022-11-22ROCHE MOLECULAR SYSTEMS, INC.$900Consulting FeeCash or cash equivalent Device2022
2022-11-19Linde Gas & Equipment Inc.$733Space rental or facility fees (teaching hospital only)In-kind items and servicesMM NO800NI-AQ Device, Respiratory2022
2022-11-18Penumbra, Inc.$949Research paymentCash or cash equivalentArtemis Device, NeurosurgeryMIND2022
2022-11-17Medical Device Business Services, Inc.$500Space rental or facility fees (teaching hospital only)Cash or cash equivalent2022
2022-11-17UROGEN PHARMA, INC.$230Research paymentIn-kind items and servicesUROGEN PHARMA BL0112022
2022-11-17UROGEN PHARMA, INC.$214Research paymentIn-kind items and servicesUROGEN PHARMA BL0112022
2022-11-16bioMerieux Inc$1,304Research paymentCash or cash equivalentPrevalence of Pathogens in Synovial Fluid Obtained From Emergency Department Patients and Clinical and Laboratory Featur2022
2022-11-16ModernaTX, Inc.$696Research paymentCash or cash equivalentModerna Covid-19 Vaccine Biological, Infections and Infectious DiseasesA Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled2022
2022-11-15Medtronic, Inc.$10,000GrantCash or cash equivalent2022
2022-11-14ModernaTX, Inc.$23,455Research paymentCash or cash equivalentModerna Covid-19 Vaccine Biological, Infections and Infectious DiseasesA Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled2022
2022-11-14ModernaTX, Inc.$10,322Research paymentCash or cash equivalentModerna Covid-19 Vaccine Biological, Infections and Infectious DiseasesA Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled2022
2022-11-14ModernaTX, Inc.$6,877Research paymentCash or cash equivalentModerna Covid-19 Vaccine Biological, Infections and Infectious DiseasesA Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled2022
2022-11-14Regeneron Pharmaceuticals, Inc.$6,684Research paymentCash or cash equivalentA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY IN CAT-ALLERGIC PATIENTS WITH ALLERGIC RHINITIS WHO LIVE WITH A CAT2022
2022-11-11PFIZER INC.$442Research paymentCash or cash equivalent2022
2022-11-10Arthrex, Inc.$22,797Research paymentCash or cash equivalentPilot Study: Safety of IOBP for MODIC2022
2022-11-10Optinose US, Inc.$2,189Research paymentCash or cash equivalentA 24-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Sa2022
2022-11-10ALK-Abello, Inc$1,744Research paymentCash or cash equivalentOdactra Drug, Allergy and ImmunologyMT-122022
2022-11-09ModernaTX, Inc.$543Research paymentCash or cash equivalentModerna Covid-19 Vaccine Biological, Infections and Infectious DiseasesA Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled2022
2022-11-09Tandem Diabetes Care, Inc.$250Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt:slim X2 Insulin Pump with Control-IQ Device, Endocrinology2022
2022-11-08Siemens Medical Solutions USA, Inc.$40,000Research paymentCash or cash equivalentADVIA Centaur XP Analyzer Device, DX - Diagnostics incl. all products and servicesCov2Ag sample collection2022
2022-11-08Siemens Medical Solutions USA, Inc.$6,869Research paymentCash or cash equivalentArtis icono floor Device, AT - Fixed interventional x-ray/angiography fluoroscopyMU Hirai icono dose reduction AT Clinical2022
2022-11-07Medical Device Business Services, Inc.$1,794Space rental or facility fees (teaching hospital only)Cash or cash equivalent2022
2022-11-07Medical Device Business Services, Inc.$1,794Space rental or facility fees (teaching hospital only)Cash or cash equivalent2022
2022-11-07Medical Device Business Services, Inc.$892Space rental or facility fees (teaching hospital only)Cash or cash equivalent2022
2022-11-07Medical Device Business Services, Inc.$892Space rental or facility fees (teaching hospital only)Cash or cash equivalent2022
2022-11-07Ethicon Endo-Surgery Inc.$537Research paymentCash or cash equivalentEchelon; Endopath Device, Endo-MechanicalA Prospective, Single-Arm, Multi-Center Study of the ECHELON EndopathTM Staple Line Reinforcement Device in Bariatric an2022
2022-11-07UROGEN PHARMA, INC.$153Research paymentIn-kind items and servicesUROGEN PHARMA BL0112022
2022-11-05Linde Gas & Equipment Inc.$330Space rental or facility fees (teaching hospital only)In-kind items and servicesREQNOXBOX-I Device, Respiratory2022
2022-11-03ABBVIE INC.$930Research paymentCash or cash equivalentCREON Drug, ENDOCRINOLOGYStudy to Evaluate Symptoms of Exocrine Pancreatic Insufficiency in Adult Participants With Cystic Fibrosis or Chronic Pa2022
2022-11-02LivaNova USA, Inc.$2,069Research paymentCash or cash equivalentVNS Therapy Symmetry Model 8103 Generator Device, Cardiology/Vascular DiseasesA Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Thera2022
2022-11-01UROGEN PHARMA, INC.$16,600Research paymentCash or cash equivalentBL0112022
2022-10-31UROGEN PHARMA, INC.$142Research paymentIn-kind items and servicesUROGEN PHARMA BL0112022
2022-10-28Medtronic, Inc.$89,331Research paymentCash or cash equivalentMICRA Device, PacemakersInvestigator Sponsored Research2022
2022-10-28ModernaTX, Inc.$8,217Research paymentCash or cash equivalentModerna Covid-19 Vaccine Biological, Infections and Infectious DiseasesA Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled2022
2022-10-28ModernaTX, Inc.$339Research paymentCash or cash equivalentModerna Covid-19 Vaccine Biological, Infections and Infectious DiseasesA Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled2022
2022-10-27Ipsen Pharma SAS$10,480Research paymentCash or cash equivalentDYSPORT Drug, NeurologyA Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety2022
2022-10-27EMD Serono, Inc.$1,878Research paymentCash or cash equivalentA Randomized, Double-Blind Placebo-Controlled, Phase 3 Study of Debio 1143 in Combination With Platinum-Based Chemothera2022
2022-10-27Ipsen Pharma SAS$1,500Research paymentCash or cash equivalentDYSPORT Drug, NeurologyA Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety2022
2022-10-26LivaNova USA, Inc.$49,884Research paymentCash or cash equivalentVNS Therapy Symmetry Model 8103 Generator Device, Cardiology/Vascular DiseasesA Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Thera2022
2022-10-26ModernaTX, Inc.$8,378Research paymentCash or cash equivalentModerna Covid-19 Vaccine Biological, Infections and Infectious DiseasesA Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled2022
2022-10-26Ipsen Pharma SAS$2,073Research paymentCash or cash equivalentDYSPORT Drug, NeurologyA Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety2022
2022-10-26Ipsen Pharma SAS$1,041Research paymentCash or cash equivalentDYSPORT Drug, NeurologyA Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety2022
2022-10-26Ipsen Pharma SAS$958Research paymentCash or cash equivalentDYSPORT Drug, NeurologyA Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety2022
2022-10-25BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.$1,741Research paymentCash or cash equivalentNURTEC ODT Drug, PRIMARY CAREA Phase 2/3 Double-Blind Randomized Placebo-Controlled Safety and Efficacy Trial of BHV-3000 (rimegepant) Orally Disinte2022
2022-10-25BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.$1,741Research paymentCash or cash equivalentNURTEC ODT Drug, PRIMARY CAREA Phase 2/3 Double-Blind Randomized Placebo-Controlled Safety and Efficacy Trial of BHV-3000 (rimegepant) Orally Disinte2022
2022-10-25BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.$1,741Research paymentCash or cash equivalentNURTEC ODT Drug, PRIMARY CAREA Phase 2/3 Double-Blind Randomized Placebo-Controlled Safety and Efficacy Trial of BHV-3000 (rimegepant) Orally Disinte2022
2022-10-25BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.$1,417Research paymentCash or cash equivalentNURTEC ODT Drug, PRIMARY CAREA Phase 2/3 Double-Blind Randomized Placebo-Controlled Safety and Efficacy Trial of BHV-3000 (rimegepant) Orally Disinte2022
2022-10-25BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.$1,417Research paymentCash or cash equivalentNURTEC ODT Drug, PRIMARY CAREA Phase 2/3 Double-Blind Randomized Placebo-Controlled Safety and Efficacy Trial of BHV-3000 (rimegepant) Orally Disinte2022
2022-10-24Merck Sharp & Dohme LLC$1,965Research paymentCash or cash equivalentLENVIMA Drug, ONCOLOGYA Phase 3, randomized, double-blind trial of pembrolizumab MK-3475 with or without lenvatinib E7080,MK-7902 in participa2022
2022-10-24Novo Nordisk AS$1,310Research paymentCash or cash equivalentOzempic Drug, DiabetesNN9535-44162022
2022-10-22Grifols Therapeutics LLC$6,726Research paymentCash or cash equivalentAlbutein Biological, Critical Care MedicinePrevention of Mortality With Long-Term Administration of Human Albumin in Subjects With Decompensated Cirrhosis and Asci2022
2022-10-21BioMarin Pharmaceutical Inc.$7,061Research paymentCash or cash equivalentAn Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia2022
2022-10-20Novocure Inc.$1,350Research paymentCash or cash equivalentEF-25 Pivotal, open-label, randomized study of radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 b2022
2022-10-20Regeneron Pharmaceuticals, Inc.$662Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYREGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID)2022
2022-10-19Innovation Technologies Inc$5,840Research paymentCash or cash equivalentIRRISEPT Device, JET LAVAGE DEVICE WITH CHGPROSPECTIVE RANDOMIZED CONTROL TRIAL COMPARING TEMPORARY EXTERNAL FIXATOR TO ANTIBIOTIC-COATED IM NAIL FOR OPEN TIBIA FR2022
2022-10-19Merz Pharmaceuticals, LLC$4,028Research paymentCash or cash equivalentXeomin Biological, MusculoskeletalProspective, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of N2022
2022-10-19Tandem Diabetes Care, Inc.$500Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt:slim X2 Insulin Pump with Control-IQ Device, Endocrinology2022
2022-10-18ABBVIE INC.$1,500Research paymentCash or cash equivalentCREON Drug, ENDOCRINOLOGYStudy to Evaluate Symptoms of Exocrine Pancreatic Insufficiency in Adult Participants With Cystic Fibrosis or Chronic Pa2022
2022-10-18ABBVIE INC.$1,500GrantCash or cash equivalentVUITY Drug, OPHTHALMOLOGY2022
2022-10-18Regeneron Pharmaceuticals, Inc.$1,455Research paymentCash or cash equivalentLIBTAYO Biological, ONCOLOGYA RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION T2022
2022-10-17Medical Device Business Services, Inc.$2,041Space rental or facility fees (teaching hospital only)Cash or cash equivalent2022
2022-10-17Medical Device Business Services, Inc.$2,041Space rental or facility fees (teaching hospital only)Cash or cash equivalent2022
2022-10-17PFIZER INC.$492Research paymentCash or cash equivalent2022
2022-10-14ModernaTX, Inc.$3,930Research paymentCash or cash equivalentModerna Covid-19 Vaccine Biological, Infections and Infectious DiseasesA Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled2022
2022-10-14Stryker Corporation$1,500Research paymentCash or cash equivalentTRITANIUM Device, HIPSTRIATHLON TRITANIUM CONE AUGMENTS OUTCOMES STUDY2022
2022-10-13MicroVention, Inc.$500GrantCash or cash equivalent2022
2022-10-12Tandem Diabetes Care, Inc.$550Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt:slim X2 Insulin Pump with Control-IQ Device, Endocrinology2022
2022-10-10Advanced Accelerator Applications$209,757Compensation for services other than consulting, including serving as faculty or as a speaker at a v (5 payments)Cash or cash equivalentLUTATHERA Drug, Oncology2022
2022-10-10Advanced Accelerator Applications$209,757Compensation for services other than consulting, including serving as faculty or as a speaker at a v (5 payments)Cash or cash equivalentLUTATHERA Drug, Oncology2022
2022-10-10Advanced Accelerator Applications$209,132Compensation for services other than consulting, including serving as faculty or as a speaker at a v (6 payments)Cash or cash equivalentLUTATHERA Drug, Oncology2022
2022-10-10Advanced Accelerator Applications$61,722Compensation for services other than consulting, including serving as faculty or as a speaker at a v (4 payments)Cash or cash equivalentLUTATHERA Drug, Oncology2022
2022-10-07ModernaTX, Inc.$54,578Research paymentCash or cash equivalentModerna Covid-19 Vaccine Biological, Infections and Infectious DiseasesA Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled2022
2022-10-07Penumbra, Inc.$425Research paymentCash or cash equivalentArtemis Device, NeurosurgeryMIND2022
2022-10-07ModernaTX, Inc.$262Research paymentCash or cash equivalentModerna Covid-19 Vaccine Biological, Infections and Infectious DiseasesA Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled2022
2022-10-05ModernaTX, Inc.$36,394Research paymentCash or cash equivalentAn Open-Label, Phase 3 Study to Evaluate the Safety and Immunogenicity of the mRNA1273.214 Vaccine for SARS-CoV-2 Varian2022
2022-10-05Veryan Medical Incorporated$26,979Research paymentCash or cash equivalentBioMimics 3D Vascular Stent System Device, Vascular StentA prospective, multicentre observational study to evaluate the BioMimics 3D1 Vascular Stent System in the treatment of p2022
2022-10-05Veryan Medical Incorporated$14,265Research paymentCash or cash equivalentBioMimics 3D Vascular Stent System Device, Vascular StentA prospective, multicentre observational study to evaluate the BioMimics 3D1 Vascular Stent System in the treatment of p2022
2022-10-05Veryan Medical Incorporated$6,847Research paymentCash or cash equivalentBioMimics 3D Vascular Stent System Device, Vascular StentA prospective, multicentre observational study to evaluate the BioMimics 3D1 Vascular Stent System in the treatment of p2022
2022-10-05Veryan Medical Incorporated$1,633Research paymentCash or cash equivalentBioMimics 3D Vascular Stent System Device, Vascular StentA prospective, multicentre observational study to evaluate the BioMimics 3D1 Vascular Stent System in the treatment of p2022
2022-10-03ModernaTX, Inc.$46,825Research paymentCash or cash equivalentModerna Covid-19 Vaccine Biological, Infections and Infectious DiseasesA Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled2022
2022-09-30Medical Device Business Services, Inc.$8,500Research paymentCash or cash equivalentDePuy Synthes Lower Extremity Shaft Nail Registry (RFN-Advanced Retrograde Femoral Nailing System/ TN-Advanced Tibial Na2022
2022-09-30Exelixis Inc.$1,000Space rental or facility fees (teaching hospital only)Cash or cash equivalentCabometyx Drug, Oncology2022
2022-09-29Medical Device Business Services, Inc.$654Research paymentCash or cash equivalentDePuy Synthes Lower Extremity Shaft Nail Registry (RFN-Advanced Retrograde Femoral Nailing System/ TN-Advanced Tibial Na2022
2022-09-28ModernaTX, Inc.$1,843Research paymentCash or cash equivalentModerna Covid-19 Vaccine Biological, Infections and Infectious DiseasesA Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled2022
2022-09-28BioMarin Pharmaceutical Inc.$1,492Research paymentCash or cash equivalentAn Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia2022
2022-09-28LivaNova USA, Inc.$1,146Research paymentCash or cash equivalentVNS Therapy Symmetry Model 8103 Generator Device, Cardiology/Vascular DiseasesA Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Thera2022
2022-09-28Tandem Diabetes Care, Inc.$250Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt:slim X2 Insulin Pump with Control-IQ Device, Endocrinology2022
2022-09-28BioMarin Pharmaceutical Inc.$196Research paymentCash or cash equivalentAn Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia2022
2022-09-27Advanced Accelerator Applications$43,804Compensation for services other than consulting, including serving as faculty or as a speaker at a v (3 payments)Cash or cash equivalentLUTATHERA Drug, Oncology2022
2022-09-27Advanced Accelerator Applications$37,806Compensation for services other than consulting, including serving as faculty or as a speaker at a v (5 payments)Cash or cash equivalentLUTATHERA Drug, Oncology2022
2022-09-27Advanced Accelerator Applications$24,332Compensation for services other than consulting, including serving as faculty or as a speaker at a v (4 payments)Cash or cash equivalentLUTATHERA Drug, Oncology2022
2022-09-26ModernaTX, Inc.$1,843Research paymentCash or cash equivalentModerna Covid-19 Vaccine Biological, Infections and Infectious DiseasesA Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled2022
2022-09-26ModernaTX, Inc.$1,834Research paymentCash or cash equivalentModerna Covid-19 Vaccine Biological, Infections and Infectious DiseasesA Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled2022
2022-09-26Innovation Technologies Inc$1,111Research paymentCash or cash equivalentIRRISEPT Device, JET LAVAGE DEVICE WITH CHGPROSPECTIVE RANDOMIZED CONTROL TRIAL COMPARING TEMPORARY EXTERNAL FIXATOR TO ANTIBIOTIC-COATED IM NAIL FOR OPEN TIBIA FR2022
2022-09-24BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.$1,741Research paymentCash or cash equivalentNURTEC ODT Drug, PRIMARY CAREA Phase 2/3 Double-Blind Randomized Placebo-Controlled Safety and Efficacy Trial of BHV-3000 (rimegepant) Orally Disinte2022
2022-09-24BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.$1,417Research paymentCash or cash equivalentNURTEC ODT Drug, PRIMARY CAREA Phase 2/3 Double-Blind Randomized Placebo-Controlled Safety and Efficacy Trial of BHV-3000 (rimegepant) Orally Disinte2022
2022-09-24BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.$1,417Research paymentCash or cash equivalentNURTEC ODT Drug, PRIMARY CAREA Phase 2/3 Double-Blind Randomized Placebo-Controlled Safety and Efficacy Trial of BHV-3000 (rimegepant) Orally Disinte2022
2022-09-23CSL Behring$794Research paymentCash or cash equivalentA Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a2022
2022-09-23CSL Behring$65Research paymentCash or cash equivalentA Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a2022
2022-09-22Synthes GmbH$6,000GrantIn-kind items and services2022
2022-09-22Medtronic, Inc.$2,565Research paymentCash or cash equivalentMICRA Device, PacemakersPSR-CVG2022
2022-09-22Medtronic, Inc.$739Research paymentCash or cash equivalentMICRA Device, PacemakersPSR-CVG2022
2022-09-22Medtronic, Inc.$739Research paymentCash or cash equivalentMICRA Device, PacemakersPSR-CVG2022
2022-09-22Stryker Corporation$625Space rental or facility fees (teaching hospital only)Cash or cash equivalentVSP SYSTEM, VSP CRANIAL Device, CRANIOMAXILLOFACIAL2022

The latest 200 records of 646.

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Boone CountyColumbia city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Columbia, MO, county Boone County, MO, state Missouri; placed by its city name.

MeasurePlace (city or town)
Columbia, MO
County
Boone County, MO
State
Missouri
Population B01003128,548188,0436,191,814
Population, 2020 census P1126,254183,6106,154,913
Median age B0100229.532.739.0
Under 18 B0100118.7%20.1%22.3%
65 and over B0100111.6%13.5%17.9%
Households B1100152,56476,5622,508,227
Foreign born B050028.1%6.4%4.5%
Median household income B19013$66,498$72,758$70,702
Median family income B19113$106,412$104,323$91,360
Per capita income B19301$39,340$40,954$39,695
Poverty rate B1700119.3%16.6%12.6%
Unemployment rate B230254.0%3.8%4.0%
Civilian labor force B2302570,686102,6513,120,639
Mean commute (minutes) B0801316.418.723.5
Bachelor's degree or higher B1500356.7%51.5%32.4%
Housing units B2500156,05481,6752,825,287
Owner-occupied B2500348.7%57.7%68.1%
Renters B2500351.3%42.3%31.9%
Median home value B25077$284,600$272,800$230,300
Median gross rent B25064$1,097$1,088$1,033
White, not Hispanic B0300271.7%75.8%76.3%
Black B0300212.1%9.5%10.9%
Hispanic or Latino B030024.4%4.5%5.2%
Asian B030026.3%4.8%2.1%
American Indian and Alaska Native B030020.1%0.1%0.2%

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Columbia, MO.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.